Condition
JAK Inhibitor
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (2)
Trial Status
Unknown2
Enrolling By Invitation1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06999941Enrolling By Invitation
A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features
NCT06925048Phase 2Not Yet Recruiting
SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC
NCT05121298Phase 3Unknown
Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate
NCT05090410Phase 3Unknown
Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
Showing all 4 trials